The Impact of Surgical Technique on Circulating Tumor DNA in Stage I-III Non-Small Cell Lung Cancer
About this study
This clinical trial compares the effect of pulmonary vein-first surgical technique to pulmonary artery-first surgical technique in decreasing circulating tumor cell deoxyribonucleic acid (ctDNA) in patients with stage I-III non-small cell lung cancer. Pulmonary vein first and pulmonary artery first surgical techniques are standard surgical techniques for the division of the blood vessels during lung resection surgery. Pulmonary vein-first surgical technique may reduce the risk of shedding tumor cells during surgery and influence long term overall survival.
- Condition
- Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8
- Tested
- Pulmonary Artery-First Surgical Technique, Biospecimen Collection
- Sponsor
- Thomas Jefferson University
Who can join
- Age
- 18 years and older
- Sex
- All sexes
- Healthy volunteers
- Not accepted
Inclusion 4
- Minimum age: 18 years
- Study condition: Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8
- Any patients 18 years of age or older with confirmed or suspected early-stage (stage I-III) NSCLC
- Eligible and scheduled for surgical anatomic lung resection (e.g. lobectomy or segmentectomy) as routine clinical care for their disease
Exclusion 3
- Previous cancer diagnosis within 5 years (except ductal carcinoma in situ \[DCIS\] of the breast, superficial bladder cancer, non-melanoma skin primary, other malignancy that does not require treatment).
- Preoperative chemotherapy, immunotherapy, or radiation therapy
- Receipt of perioperative blood transfusion
Where
4 sites, 4 recruiting
Abington Memorial Hospital
Abington, Pennsylvania, United States
Jefferson Health Northeast
Philadelphia, Pennsylvania, United States
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania, United States
Asplundh Cancer Pavilion at Jefferson Health
Willow Grove, Pennsylvania, United States
Contact
-
Tyler Grenda, MD
215-955-5562 Tyler.grenda@jefferson.edu
Potential match only. Final eligibility is determined by the study team.